Treatment outcomes of IgG4-producing marginal zone B-cell lymphoma: a retrospective case series
Autor: | Nobuharu Fujii, Yoshinobu Maeda, Hisakazu Nishimori, Masanori Makita, Yasuharu Sato, Daisuke Ennishi, Yuka Sogabe, Yusuke Yoshimoto, Koh Ichi Ohshima, Yusuke Meguri, Ken-ichi Matsuoka, Yuichi Sumii, Tadashi Yoshino, Noboru Asada, Kenji Imajo |
---|---|
Rok vydání: | 2020 |
Předmět: |
medicine.medical_specialty
Chemotherapy business.industry medicine.medical_treatment Combination chemotherapy Retrospective cohort study Hematology medicine.disease Gastroenterology Lymphoma 03 medical and health sciences 0302 clinical medicine 030220 oncology & carcinogenesis Internal medicine Localized disease medicine Marginal zone B-cell lymphoma IgG4-related disease Rituximab business 030215 immunology medicine.drug |
Zdroj: | International Journal of Hematology. 112:780-786 |
ISSN: | 1865-3774 0925-5710 |
DOI: | 10.1007/s12185-020-02968-w |
Popis: | IgG4-producing marginal zone B-cell lymphomas (MZLs) have been recently proposed as a subtype of MZLs. Despite the abundant literature on pathophysiological features of this type of lymphoma, only a few retrospective studies pertaining to the treatment outcomes have been reported, and its prognosis remains unclear. We retrospectively analyzed seven patients with IgG4-producing MZLs diagnosed at our institute, with specific reference to treatment and outcomes. The median age was 69.0 years (55–79), and all were males. The median follow-up period was 66.6 months (8–121). All patients had localized disease; four patients had tumors of the ocular adnexa, whereas two had retroperitoneal tumors. Five patients were treated with irradiation (30 Gy/15 fr) (n = 4) or surgery (n = 1), resulting in tumor reduction. Two patients were treated by chemotherapy or irradiation. Among them, one commenced rituximab monotherapy, which led to an inadequate reduction of the tumor. Subsequent irradiation induced complete response (CR). The other patient experienced repeated relapses during follow-up and finally achieved CR by combination chemotherapy. Treatment was well tolerated in all cases, and none of the patients showed disease progression at the last follow-up visit. Our results indicate that the standard treatments for MZLs are generally appropriate for IgG4-producing MZL. |
Databáze: | OpenAIRE |
Externí odkaz: |